APIFINY — The Non-PSA Blood Test for Prostate Cancer
This new technology is for use by primary care physicians, urologists, and oncologists alike.
APIFINY takes advantage of a man’s own immune system to test for autoantibodies produced in response to the early onset of prostate cancer. Such autoantibodies are detectable in a patient’s serum, providing the basis for Armune’s diagnostic blood test.
APIFINY measures the body’s immune-system response to prostate cancer and may help clinicians confirm the presence or absence of cancer. It is well known that early detection improves long-term survival rates, therefore this technology may potentially have a profound effect on the detection and treatment of cancer.
Breakthrough Science in the Early Detection and Diagnosis of Cancer
In the case of most cancers, the earlier the detection, the better chance for recovery. Scientific discovery has come a long way in the detection of lung, breast, and prostate cancers. However, there remains a potential for missed diagnosis. Armune BioScience was founded on the mission to improve the detection of cancer and enhance the outcome of therapies to treat cancer. Our technology is based on peer-reviewed and validated scientific research that detects autoantibodies produced by the body’s immune system in response to the onset of cancer.
What is Prostate Cancer and How is it Detected?
Prostate cancer is the most common non-skin cancer in America, affecting 1-in-7 men. In this section, we provide an overview of prostate cancer and the methods currently available to test and assess risk for, diagnose, and treat the disease.